Now available K2 in Menaquinone 7 (MK7) form
Ingredients
K2
Medium chain triglycerides
Vitamin E (d alpha tocopherol) (0.1mg total)
Each drop contains 55 µgs of MK7 equivalent to approximately 60% NRV
What are the benefits of K2 from MK7
Superior bioavailability and longer half-life: MK-7 remains in the bloodstream longer (up to several days) compared to shorter forms like MK-4, allowing for sustained activation of vitamin K-dependent proteins at lower daily doses (typically 90-360 μg).
Supports bone health: Improves bone mineral density (BMD), particularly in the lumbar spine and femoral neck; reduces age-related bone loss; enhances osteocalcin carboxylation; and promotes bone quality and strength in postmenopausal women.
Reduces fracture risk: Associated with lower vertebral fracture rates (up to ~60% reduction in some observational data) and helps preserve trabecular bone microarchitecture.
Cardiovascular benefits: Decreases arterial stiffness, improves vascular elasticity (even reversing age-related stiffening in some trials), and inhibits arterial calcification by activating matrix Gla protein (MGP).
Potential metabolic improvements: May enhance insulin sensitivity, lower HbA1c, and improve glycemic control in certain populations.
Anti-inflammatory and other effects: Shows promise in reducing inflammation, supporting endothelial function, and potential benefits for conditions like peripheral neuropathy, diabetes, and age-related diseases.
Safe at recommended doses: Well-tolerated with no serious adverse effects in clinical trials, and does not interfere with normal coagulation in healthy individuals.
MK-7 achieves greater "effective volume" in the body through prolonged presence and better extrahepatic distribution at nutritional doses (90-360 μg/day). MK-4 requires much higher pharmacological doses (e.g., 15-45 mg/day, often divided) for comparable systemic effects, primarily used in clinical settings for bone health.These differences explain why MK-7 is often favoured for cardiovascular and general long-term benefits, while high-dose MK-4 has strong evidence for bone fracture prevention.
Now available K2 in Menaquinone 7 (MK7) form
Ingredients
K2
Medium chain triglycerides
Vitamin E (d alpha tocopherol) (0.1mg total)
Each drop contains 55 µgs of MK7 equivalent to approximately 60% NRV
What are the benefits of K2 from MK7
Superior bioavailability and longer half-life: MK-7 remains in the bloodstream longer (up to several days) compared to shorter forms like MK-4, allowing for sustained activation of vitamin K-dependent proteins at lower daily doses (typically 90-360 μg).
Supports bone health: Improves bone mineral density (BMD), particularly in the lumbar spine and femoral neck; reduces age-related bone loss; enhances osteocalcin carboxylation; and promotes bone quality and strength in postmenopausal women.
Reduces fracture risk: Associated with lower vertebral fracture rates (up to ~60% reduction in some observational data) and helps preserve trabecular bone microarchitecture.
Cardiovascular benefits: Decreases arterial stiffness, improves vascular elasticity (even reversing age-related stiffening in some trials), and inhibits arterial calcification by activating matrix Gla protein (MGP).
Potential metabolic improvements: May enhance insulin sensitivity, lower HbA1c, and improve glycemic control in certain populations.
Anti-inflammatory and other effects: Shows promise in reducing inflammation, supporting endothelial function, and potential benefits for conditions like peripheral neuropathy, diabetes, and age-related diseases.
Safe at recommended doses: Well-tolerated with no serious adverse effects in clinical trials, and does not interfere with normal coagulation in healthy individuals.
MK-7 achieves greater "effective volume" in the body through prolonged presence and better extrahepatic distribution at nutritional doses (90-360 μg/day). MK-4 requires much higher pharmacological doses (e.g., 15-45 mg/day, often divided) for comparable systemic effects, primarily used in clinical settings for bone health.These differences explain why MK-7 is often favoured for cardiovascular and general long-term benefits, while high-dose MK-4 has strong evidence for bone fracture prevention.
